Hersle K, Mobacken H, Moberg S
Int J Dermatol. 1985 May;24(4):245-8. doi: 10.1111/j.1365-4362.1985.tb05773.x.
Ketoconazole 200-400 mg was given once daily for a maximum period of 12 months to 31 patients with chronic (mean duration, 12 years) dermatophyte infections of the hands and/or feet. Griseofulvin had previously been withdrawn due to intolerance or lack of effect. All skin and nail infections improved clinically. Fifty percent of the patients with skin infections and 26% of those with nail infections became clinically clear and culture-negative. Six months later, relapses had occurred in 8 of 12 patients (67%) with cleared skin lesions, and in 2 of 5 (40%) with cleared nail infections. Ketoconazole was discontinued in one patient due to headache and in another due to asymptomatic transient elevation of hepatic laboratory tests. Ketoconazole is an alternative when a replacement for griseofulvin is required, provided the degree of disability justifies the risk of drug toxicity.
对31例慢性(平均病程12年)手足皮肤癣菌感染患者给予酮康唑200 - 400mg,每日1次,最长治疗12个月。此前,由于不耐受或疗效不佳,已停用灰黄霉素。所有皮肤和指甲感染在临床上均有改善。50%的皮肤感染患者和26%的指甲感染患者临床症状消失且培养阴性。6个月后,12例皮肤病变已清除的患者中有8例(67%)复发,5例指甲感染已清除的患者中有2例(40%)复发。1例患者因头痛停用酮康唑,另1例患者因肝脏实验室检查无症状短暂升高而停药。当需要替代灰黄霉素时,酮康唑是一种选择,但前提是残疾程度证明药物毒性风险是合理的。